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Osteoblasts are important regulators of myelopoiesis and lymphopoiesis, producing several necessary
soluble and membrane-associated factors. In addition, they may play important roles, along with other
mesenchymal populations, in constructing an environment that is suitable for development of sinusoidal
niches capable of supporting hematopoietic stem cells.The Hematopoietic Stem Cell Niche Hypothesis
Hematopoietic stem cells (HSCs) are tasked with the de novo
generation and lifelong maintenance of all the cells comprising
the vertebrate blood system. They do so through the balanced
production of new HSCs, referred to as HSC self-renewal, and
more mature and increasingly lineage-restricted progenitors,
referred to as differentiation. The functions of HSCs and those
downstream progenitors and precursors ultimately responsible
for the maturation and proliferation of mature cell numbers are
controlled by factors both intrinsic and extrinsic to the specific
cells. It is hypothesized that specific microenvironments, or
‘‘niches,’’ exist within the bone marrow that organize these
factors in order to support specific aspects of hematopoiesis,
such as HSC survival, self-renewal, and differentiation.
Osteoblasts Regulate Myelopoiesis and Lymphopoiesis
Given that, at steady state, adult hematopoiesis takes place
exclusively in bone, a tie between the formation of blood cells
and some unique character of bone has long been suggested.
After all, while definitive HSCs arise in the aorta-gonad-meso-
nephros of the mammalian embryo and shortly thereafter move
to the fetal liver, there is a rapid and permanent perinatal shift
of the entire hematopoietic system to the bone cavity. While
the exact combination of cellular and noncellular components
that define these hematopoietic microenvironments (HMEs) is
slowly becoming clearer, it is almost certain that bone- and/or
marrow-specific elements drive much of this HSC localization.
A specific role for osteoblasts in supporting the survival
and/or differentiation of hematopoietic stem and progenitor cells
(HSPCs) was hypothesized based on the proximity of both cell
types to the bone endosteum (Taichman and Emerson, 1994).
Osteoblasts and bone marrow stromal cells (BMSCs) exist at
the endosteum, playing critical roles in bone homeostasis,
including the following: (1) formation of new bone through the
mineralization of a type I collagenmatrix; and (2) regulation of os-
teoclastogenesis, bone resorbing cells. Uncovering this latter
role demonstrated that osteoblasts, in addition to their primary
osteogenic function, also regulate the fate of hematopoietic
cells, as osteoclasts are derived from a monocytic precursor.
More recently, the production of bone matrix, the regulation of
free calcium concentrations, and the presence of specific adhe-sive niches on osteoblast or osteoprogenitor surfaces have all
been implicated in the adhesion and quiescence of HSCs.
The first direct role discovered for osteoblasts in blood
cell production was the support of terminal granulopoiesis.
While it was known that bone marrow fibroblasts were capable
of producing myeloid-specific cytokines such as granulocyte
colony-stimulating factor (G-CSF) and granulocyte monocyte
colony-stimulating factor (GM-CSF) in response to inflammation,
the source of basal granulocyte production was unknown. Taich-
man and Emerson (1994) demonstrated that osteoblast mono-
layers induced the differentiation of some CD34+ bone marrow
cells to mature neutrophils, at least in part due to G-CSF produc-
tion. Most recently, in vivo studies confirmed that loss of osteo-
blasts leads to a rapid and significant reduction in the number of
cKit+ promyelocytes, as well as more mature granulocytes and
monocytes (Zhu et al., 2007). Other hematopoietic-relevant
molecules, such as IL-6, are expressed by human osteoblasts
and contribute to their support of in vitro hematopoiesis (Taich-
man and Emerson, 1994; Taichman et al., 1997). Interestingly,
secretion of certain cytokines such as IL-6 andGM-CSF appears
to be dynamically regulated. Stimulation of osteoblasts with
parathyroid hormone (PTH) increases their production of IL-6
and GM-CSF. Additionally, it was found that coculturing primary
cells enriched for HSCs with osteoblasts increased the secretion
of leukemia inhibitory factor, IL-6, and stromal-derived factor 1
(SDF-1) by osteoblasts (Jung et al., 2008; Taichman et al.,
1997). This principle of retrograde HSC-to-osteoblast communi-
cation was recently reinforced by Jung et al. (2008), who found
that HSPCs could increase the proliferation and differentiation
of BMSCs into osteoblastic cells through secretion of bone
morphogenic proteins. In vivo data using neonatal vertebral
bone transplantation supported the finding, and data from aging
or myeloablated mice demonstrate the dynamic nature of this
phenomenon (Jung et al., 2008).
Osteoblasts are also required for B lymphopoiesis. Taking
advantage of an osteoblast-specific thymidine kinase linked to
2.3KbCol1A1, which permits targeted destruction of osteoblasts
following ganciclovir administration, Visnjic et al. (2004) found
a complete loss of B cells 25 days after drug treatment. Expand-
ing on those preliminary results, Zhu et al. (2007) demonstrated
that pre-pro-B and pro-B cells are reduced by greater thanCell Stem Cell 4, June 5, 2009 ª2009 Elsevier Inc. 503
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HSCs. In addition, osteoblasts were able to support the genera-
tion of all stages of B lymphopoiesis, including the sIgM+ imma-
ture B cell stage, in vitro (Zhu et al., 2007). The necessity for
specific adhesion and signaling molecules such as VCAM-1, a4
integrin, and IL-7 was demonstrated. Interestingly, while supple-
mentation with PTHwas not necessary for osteoblast-supported
in vitro B lymphopoiesis, it was found to be stimulatory, possibly
working through some combination of SDF-1 and IL-7 (Zhu
et al., 2007). The absolute requirement for osteoblasts in B lym-
phopoiesis was recently confirmed using the Osterix promoter
to delete Gsa, a downstream mediator of PTH/PTH-related
peptide receptor (PPR), resulting in a loss of early B cell precur-
sors including pro-B cells and a concomitant loss of IL-7 produc-
tion. Interestingly, the numbers of pre-pro-B cells were normal,
indicating a role for PTH in the transition to the pro-B stage, but
not earlier (Wu et al., 2008). Together, these three studies show
a critical role for osteoblasts during in vivo B lymphopoiesis,
and the ability for osteoblasts to support in vitro B lymphopoiesis.
While osteoblasts are the site of HSC differentiation through
the earliest stages of B lymphopoiesis, later maturation appears
to occur preferentially at bone marrow sinusoids, specialized
thin-walled blood vessels. Recent data show that the homing
to and engraftment in the sinusoidal niche requires the action
of cannabinoid receptor 2 (CB2), another G protein-coupled
receptor, and interaction between a4 integrin and its receptor
VCAM-1 (Pereira et al., 2009). Interruption of CB2 via gene
knockout or receptor antagonism reduced the retention time in
the bone marrow sinusoids and resulted in a decreased number
of l+ B cells in the periphery, interpreted as increased cell death
due to inappropriate repertoire development/selection (Pereira
et al., 2009). The above studies demonstrate the importance of
multiple niches involved at different stages of a common devel-
opmental program and may prove to be important in under-
standing other hematopoietic niches in the bone marrow.
The Relationship of Osteoblasts to Sites
of HSC Self-Renewal and Proliferation
Whereas evidence for osteoblasts’ roles in B lymphopoiesis and
granulopoiesis is clear and consistent, what do we know about
the role of osteoblasts in HSC maintenance, self-renewal,
and proliferation? As stated earlier, the hypothesis that osteo-
blasts represent an important regulatory component of HSC
biology is not new, but recent experiments demonstrating that
increasing the numbers of osteoblasts, either through inactiva-
tion of the BMP receptor type 1A (BMPR1A) or constitutive
activation of the PPR, leads to a concomitant increase in the
number of HSCs, and that donor HSCs can be detected adjacent
to osteoblasts (Calvi et al., 2003; Zhang et al., 2003), has impli-
cated osteoblasts as the site of HSC homing and survival.
Much has been written about these two studies, and we believe
an in-depth discussion in this document is not necessary.
However, we note that these data should be interpreted in light
of the particulars of the experimental systems used. For
example, in order to introduce constitutively active PPR to oste-
oblasts, Calvi et al. (2003) used 2.3KbCol1A1, which potentially
targets more immature osteoprogenitors. Zhang et al. (2003)
knocked out BMPRIA using an inducible Mx1-Cre system,
arguing that the nonspecificity of the promoter did not confound504 Cell Stem Cell 4, June 5, 2009 ª2009 Elsevier Inc.their results because they could not find detectable levels of
BMPR1A mRNA in HSCs. Since then, others have found that
human CD34+ bone marrow cells do express BMPR1A and
that signaling through this receptor had some, but limited,
capacity to regulate the numbers of primitive HSPC in vitro
(Grassinger et al., 2007). This caveat does not rule out the possi-
bility that a relationship does exist between the numbers of
osteoblasts and the numbers of HSCs. In fact, our lab and others
found that while losses were detected in the lymphocytic and
myelocytic compartments very early on following in vivo deple-
tion of osteoblasts, there was an eventual loss of LSK cells,
which include HSCs, from the marrow of those mice after
28 days. Additionally, osteoblasts were able to support LSK cells
in vivo, with the addition of external factors including SCF and
interleukins (Visnjic et al., 2004; Zhu et al., 2007).
Very recently, two papers have used similar approaches to
identify where purified Flk2 LSKs home in the bone marrow
(Lo Celso et al., 2009; Xie et al., 2009). In the case of Lo Celso
et al. (2009), the entire experiment was performed in vivo with
live animal imaging of calvaria. Xie et al. (2009) harvested leg
bones shortly after transferring HSCs and imaged them in semi-
solid media. In both studies, imaging occurred within 5 hr of HSC
transfer, and both irradiated and nonirradiated mice were used
as recipients. Neither study attempted to identify the location
of host HSCs, as had been done previously (Kiel et al., 2005).
Striking similarities were found between the two studies
regarding to where HSCs home under normal and myeloablated
scenarios. In both cases, HSCs homed to areas away from the
endosteum and closer to vascular endothelium in nonirradiated
mice. Lo Celso et al. (2009) found that after 5 hr, donor HSCs
were 0–16 mm from vasculature but more than 30 mm from the
endosteum. Likewise, in the second study, 25 of 32 (78%) cells
counted were located more than four cell depths (defined by
the investigators as one cell depth = 6–8 mm) from the endos-
teum. No information was given regarding proximity to vascula-
ture, but it was noted that the vasculature was distributed
throughout the bone marrow cavity, including at the endosteum
(Xie et al., 2009). Likewise, Lo Celso et al. (2009) found that there
is extensive vascularization of the endosteum, with 60% and
90% of osteoblasts within 10 or 20 mm of vasculature, respec-
tively. Hooper et al. (2009) imaged VEGFR3+ sinusoidal endothe-
lium in very close proximity to osteoblasts. These studies agree
with a previously published report identifying HSCs in untreated
mice as being adjacent to sinusoidal endothelium. Using the
refined HSC phenotype of LinCD41CD48CD150+, only
14% of HSCs were found in close contact with the endosteum,
while 60% were in contact with sinusoidal endothelium in the
bone marrow, and 62% were in contact with splenic sinusoids.
Additionally, these areas were significantly enriched for HSCs
over other hematopoietic populations (Kiel et al., 2005).
Following irradiation and destruction of vascular sinusoids,
both studies noted that donor HSCs homed closer to the endos-
teum. In the first study, fluorescently labeled HSCs were located
between 0 and 40 mmof the endosteum when transferred to irra-
diated recipients (Lo Celso et al., 2009). No information was
given regarding changes in distance to vasculature. In the
second study, 28 of 43 (65%) donor HSCs counted were now
located within four cell depths of the endosteum, with only 15
of 43 (35%) farther out (Xie et al., 2009). Similar to the Lo Celso
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HSC endosteal distance following irradiation. A possible inter-
pretation of these investigations is that under steady-state
conditions, the physiological HSC niche exists at the heavily vas-
cularized endosteum but is saturated with host HSCs, forcing
transplanted cells to adhere to alternate niches, including the
immature B cell niche identified in the sinusoids (Pereira et al.,
2009). Following irradiation and the destruction of host HSCs,
these endosteal niches are available for engraftment by trans-
plants. Notably, Lo Celso et al. also demonstrated that HSCs
transplanted into WWv recipients, which do not require irradia-
tion to yield high chimerism, localized close to osteoblasts,
correlating homing distances with the degree of donor cell
reconstitution. Due to the strong evidence that HSCs are located
adjacent to sinusoids and away from the endosteum at steady
state, it is more likely that transplanted cells home to the perivas-
cular location under nonirradiated conditions because it repre-
sents the preferred microenvironment. Due to low HSC engraft-
ment into normal nonmyeloablated hosts, and a normally low
frequency of HSCs entering the cell cycle, transplanted cells
are incapable of generating detectable blood cell chimerism.
Under this hypothesis, paraosteoblastic niches normally occu-
pied by early B cell progenitors may also serve as sites for
HSC homing and proliferation following irradiation-induced
loss of sinusoids, enabling hematopoietic recovery. It is also
possible, given the extensive endosteal vascularization noted
by both studies, that HSCs home to surviving sinusoids or other
stromal cells near the endosteum (Lo Celso et al., 2009; Xie et al.,
2009). Slayton et al. (2007) found that SDF-1, a potent HSC che-
mokine, was expressed at the endosteum following lethal radia-
tion, providing a plausible mechanism for this transit. It would be
of keen interest to know the location of surviving HSCs following
sublethal irradiation and how signaling to and from osteoblasts
changes following irradiation.
Sinusoidal Endothelium, the Niche,
and Hematopoietic Recovery
HSCs have been imaged residing adjacent to bone marrow sinu-
soids (Kiel et al., 2005). Bone marrow sinusoids are single-cell
walled structures with discontinuous pericytes and basal lamina,
void of tight junctions, and which receive some of their structural
support from the hematopoietic marrow, making them sensitive
to treatments that cause a rapid loss of bone marrow cellularity.
As early as 7 days postirradiation, bone marrow sinusoids are
enlargedand irregular inshape,withextensive intramarrowhemor-
rhage and limited sinusoidal endothelial cell (SEC) DNA damage
and necrosis (Li et al., 2008; Slayton et al., 2007). Repopulation
and repair of thesinusoids results from theproliferationof surviving
SECs, a process that begins shortly after irradiation and is acceler-
ated by infusion of endothelial progenitor cells (EPCs) (Li et al.,
2008;Salter etal., 2009;Slaytonetal., 2007). Intriguingly,EPC infu-
sionalsoacceleratedhematopoietic recovery in irradiatedmice, as
evidencedbynear-normal numbersof colony-formingcells (CFCs)
and a notable elevation in the number of phenotypic and functional
HSCs (Salter et al., 2009). A complementary study blocking angio-
genesis using antibodies directed against VEGFR2 showed that
concomitant with reduced restoration of the bone marrow sinu-
soids was a near-total block of donor HSPC engraftment and
hematopoietic bone marrow recovery, as measured by flowcytometry (Hooper et al., 2009). These combined data clearly link
hematopoietic recovery with sinusoidal recovery.
Moving toward a New Model of Hematopoietic
Microenvironment Development and Regulation
The positive relationship between BMSC and the HME was first
demonstrated more than 30 years ago (Friedenstein et al., 1974).
Some of the most exciting recent investigations have looked at
the ability of specific cell populations isolated from bone to
establish the HME. These studies collectively show that the
appearance of hematopoietic cells in the bone marrow first
requires the assembly of sinusoids, a process that is, at least
in part, controlled by osteoprogenitors. Subcutaneous trans-
plantation of human CD45CD146+ (additional markers include
CD105+ alkaline phosphatase+ angiopoietin-1+) colony-forming
unit fibroblasts (CFU-Fs), which appeared in situ as subendothe-
lial reticular fibroblasts, into mice resulted in the formation of
ectopic bone, complete with sinusoids and hematopoietic cells
(Sacchetti et al., 2007). Detection of donor-derived bone and
fibroblastic tissue preceeded formation of host-derived vascular
sinusoids. Shortly thereafter, hematopoietic cells were located in
the area surrounding these sinusoids (Sacchetti et al., 2007).
Interestingly, a small population of CD146+ reticular cells, func-
tional in secondary transplantations, was located adjacent to
the sinusoids. Although no attempt was made to determine
whether HSCs were supported, the investigators noted that
a rare population of hematopoietic cells expressing Tie-2, the
ligand for angiopoietin-1, and expressed by HSCs, was adjacent
to CD146+ reticular cells (Sacchetti et al., 2007).
More recently, Chan et al. (2009) identified a similar CD105+
population of murine stromal cells. When transplanted under-
neath the renal capsule, these cells were capable of generating
an ectopic HME, including donor-derived bone formed through
a cartilaginous intermediate, host-derived vasculature, and
hematopoietic cells. Unlike Sacchetti et al. (2007), the investiga-
tors confirmed the presence of HSCs but did not identify their
location (Chanet al., 2009).Gene-silencing experiments revealed
that while SCF production by the donor-derived elements was
not necessary for the initiation and maintenance of hematopoi-
esis, Osterix, associated with endochondral ossification, was
(Chan et al., 2009). As was found following irradiation-induced
damage, VEGFR2-mediated signaling is required for the forma-
tion of bone marrow sinusoids (Chan et al., 2009; Hooper et al.,
2009). Unfortunately, no attempt was made to identify whether
the CD105+ cells represented a self-renewing stem cell, as found
by Sacchetti et al. (2007). In both studies, bone formation
preceded vascularization, which itself was necessary for popula-
tion by hematopoietic cells. Intriguingly, mature cells populated
this new HME before HSCs, suggesting that structurally sound
sinusoids, receiving support from hematopoietic marrow, are
a prerequisite for HSC colonization. In addition, both studies
found that generation of bone alone was not sufficient for the
establishment of hematopoiesis (Chan et al., 2009; Sacchetti
et al., 2007). Importantly, these studies represent experimental
models, which can be used to dissect the molecular signature
of the HSC niche, as well as other lineage-specific niches.
Combined, we believe these studies reveal a genesis of the
HME that begins with a population of stromal cells constructing
a proangiogenic environment that includes critical vascularCell Stem Cell 4, June 5, 2009 ª2009 Elsevier Inc. 505
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Following initiation of the HME, HSCs are largely maintained at
these vascular sinusoids, with osteoblasts critically supporting
myelopoisis and lymphopoiesis through the production of
soluble and membrane-associated factors such as G-CSF and
IL-7. Additionally, osteoblasts provide a home for surviving and
transplanted HSPCs following myeloablative therapies, main-
taining those cells while the sinusoidal niche regenerates
(Figure 1). It is important to note that this model is but one
possible interpretation of the studies discussed above. Addition-
ally, these studies underscore that a complex array of cells with
overlapping and unclear function and morphology are present in
the marrow andmay also perform critical roles in hematopoiesis.
Final Remarks
Understanding how specific hematopoietic niches support the
maintenance of the blood system under normal and stressed
conditions is of both academic and practical importance.
Recently, much information has been gathered using innovative
approaches, such as in vivo imaging and the formation of
ectopic niches. These tools and the information gathered using
them will be refined and reinterpreted during the next few years.
As we do this, we must be mindful of the possibility that there is
not a single and simply constructed niche but that it is the totality
of the bone marrow environment that is essential for hematopoi-
esis, with a combination of distinct and overlapping roles being
Figure 1. A Model Depicting Osteoblasts, Stromal Cells/
Osteoprogenitors, and Sinusoidal Endothelium Collaborating
to Control Steady-State and Postirradiation Hematopoiesis
(A) Under steady-state conditions, HSPCs (green) are primarily located adja-
cent to sinusoids, contacting endothelial cells (red) and/or rare stromal cells
(pink). In response to chemokines and cytokines, including G-CSF and IL-7,
produced by osteoblasts (purple), these cells are capable of undergoing differ-
entiation into immature B cells (blue) or myeloid cells (yellow).
(B) Following irradiation-induced damage, sinusoids dissociate, resulting in
significant intramarrow hemorrhage. In response to a strong SDF-1 gradient,
HSPCs relocate to available niches at the osteoblast, where they are able to
contribute to restorative hematopoiesis.506 Cell Stem Cell 4, June 5, 2009 ª2009 Elsevier Inc.performed by multiple cellular and extracellular partners. These
environments are likely dynamic, altered by routinely used
experimental protocols that perturb normal in vivo hematopoi-
esis. At present, it is clear that osteoblasts and stromal cells,
endothelial cells and hematopoeitic cells interact, through
combinations of adherent and soluble factors, to create as-yet
ill-defined niches that support HSC self-renewal and differentia-
tion. Future experiments, which combine genetic tools with
high-resolution in vivo imaging, should shed more light on the
specific interactions that define each of these microniches.
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